Levodopa-carbidopa intestinal gel infusion and long-term tolerability in Parkinson’s: multicentre, international 13-year follow-up data
Objective: To evaluate the long-term range and nature of Levodopa-carbidopa intestinal gel (LCIG) infusion-related complications in people with Parkinson’s (PwP). Background: LCIG infusion is an…Continuous circadian intracerebroventricular administration of anaerobically preserved dopamine greatly reduces severe L-dopa-related complications in Parkinson’s disease
Objective: We aim to demonstrate the safety and efficacy of continuous circadian intracerebroventricular (i.c.v.) administration of anaerobic-dopamine (A-dopamine) to reduce the L-dopa-related complications (LDRC) in…Efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease patients with motor fluctuations: a multicenter randomized open-label cross-over trial
Objective: This study aimed to assess the efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease (PD) patients with motor fluctuation. Background: Delayed…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Dyskinesia
Objective: Assess impact of apomorphine sublingual film (APL) on time spent with and functional impact of dyskinesia among patients with Parkinson’s disease (PD) and “OFF”…CSF MicroRNA Analysis Reveals Angiogenesis And Autophagy Defects In Parkinson’s DiseasePatients
Objective: We investigated the effects of discoidin domain receptor (DDR)-1 inhibition on CSF miRNAs in Parkinson’s disease patients. Background: MicroRNAs (miRNAs) are post-transcriptional regulators of…Cinpanemab in Early Parkinson’s Disease: Phase 2 SPARK Study Results
Objective: To evaluate cinpanemab (BIIB054) efficacy and safety. Background: Aggregated alpha-synuclein (α-syn), a major constituent of Lewy bodies, is thought to play a central role…Predictors of antidepressant and benzodiazepine treatment in Parkinson’s disease
Objective: To assess the prevalence of antidepressant and benzodiazepine (BDZ) treatment in Parkinson’s disease (PD), to analyze treatment with respect to altered mood indication, and…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Analysis of Baseline Factors
Objective: Determine if baseline factors are associated with the apomorphine sublingual film (APL) dose required to achieve FULL “ON.” Background: APL is approved for the…A New Phase of the Parkinson’s Outcomes Project Registry Study
Objective: Objective: To provide an update on the Parkinson’s Outcomes Project, a longitudinal study measuring outcomes among people with Parkinson’s disease (PwP). Background: Background: Data…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Characterization of Acute Nausea During Dose Titration
Objective: Characterize acute episodes of nausea experienced by patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for the on-demand treatment of “OFF” episodes.…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 32
- Next Page »